Treatment of Aids With Intravenous Gammaglobulin

Rubinstein, Arye; Sicklick, Marc; Bernstein, Larry; Silverman, Bernard A.; Novick, Brian; Charytan, Morris; Krieger, Benzion

doi:10.1203/00006450-198404001-01026

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oleske et al treated a small number of children with IVIG and found that the incidence of serious bacterial infections was reduced, though the ultimate mortality was not altered (191). Rubenstein et al reported that patients treated with IVIG had an increase in the CD4/CD8 ratio and in lymphocyte transformation to phytohemagglutinin and pokeweed mitogen (192). Calvelli & Rubinstein (193) treated 14 children with an escalating dose of 50 to 300 mg/kg administered every 2 to 3 days and compared them with 27 patients not given IVIG.…”

Section: Secondary Defects Of Immunitymentioning

confidence: 99%

Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action

Schiff

1994

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Section: Secondary Defects Of Immunitymentioning

confidence: 99%

Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action

Schiff

1994

Pediatric Allergy Immunology

View full text Add to dashboard Cite

“…Unfortunately, many individuals may have the misconception that infectious diseases occur only in adults. These diseases are not limited to adult populations (42). Our results showed some variability in the policies of agencies than treated only children or adolescents versus those agencies that served only adults or all ages.…”

Section: Resultsmentioning

confidence: 70%

Barrier Techniques and Hepatitis B Vaccine Policies in Dental Components of Local Health Agencies

Kuthy

Pruitt

et al. 1988

J Public Health Dent

View full text Add to dashboard Cite

National health organizations have issued guidelines for barrier control techniques against infectious diseases and for inoculation against hepatitis B. This study surveys the policies of local health agencies regarding the safeguards used in protecting their employees. Local health agencies (N = 201) operating independently of state health departments were mailed questionnaires seeking information regarding glove, mask, and eyewear policies, as well as hepatitis B vaccine policies for new and current employees. Of the 156 programs returning the survey, 127 (76.6%) reported having a clinical component. Many agencies did not require infection control policies to be implemented for every patient. Agencies that had dental directors who have held their positions for fewer than four years were more likely to have requirements for gloves and masks than agencies run by directors with longer tenure. Those agencies that provided dental treatment to inmates at correctional institutions were also more likely to require infection control policies. The data indicate policy inconsistencies among local dental health programs nationwide. Of considerable concern is the fact that infection control was not identified as a priority for the near future. Many local health agencies would benefit from further education in infection control.

show abstract